Amag Pharmaceuticals

Years after it was OK'd, AMAG's drug for preventing preterm births fails badly in long-awaited confirmatory trial
Years after it was OK'd, AMAG's drug for preventing preterm births fails badly in long-awaited confirmatory trial
Endpoints
Amag Pharmaceuticals
Makena
preterm birth
FDA
Flag link:
Amag's in-house digital revamp puts its consumer tactics to work in pharma
Amag's in-house digital revamp puts its consumer tactics to work in pharma
Fierce Pharma
Amag Pharmaceuticals
digital pharma
consumers
Flag link:
AMAG to hire 150 new sales reps to tout newly licensed women's health med Intarosa
AMAG to hire 150 new sales reps to tout newly licensed women's health med Intarosa
Fierce Pharma
Amag Pharmaceuticals
Women's Health
hirings
drug reps
Intarosa
vaginal pain
Flag link:
With new additions, PhRMA opens door to generics drugmaker Teva
With new additions, PhRMA opens door to generics drugmaker Teva
BioPharma Dive
PhRMA
generics
Teva Pharmaceuticals
Alexion
Amag Pharmaceuticals
Horizon Pharma
Jazz Pharmaceuticals
Flag link:
4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming
4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming
24/7 Wall St
Pfizer
Sarepta Therapeutics
PTC Therapeutics
Amag Pharmaceuticals
Flag link:
AMAG buying Cord Blood Registries for $700 million
AMAG buying Cord Blood Registries for $700 million
Yahoo/AP
Amag Pharmaceuticals
M&A
Cord Blood Registries
Flag link:
Meet 5 Top Drug Stocks That Are Bolting Past Market
Meet 5 Top Drug Stocks That Are Bolting Past Market
Investors.com
Celgene
Amgen
AstraZeneca
Hospira
Amag Pharmaceuticals
Flag link:
Amag Pharma buys women's health company Lumara for $675 mln
Amag Pharma buys women's health company Lumara for $675 mln
Yahoo/Reuters
Amag Pharmaceuticals
M&A
Lumara
Women's Health
Flag link:
3 Lessons From the Biggest Biotech Event of 2014
3 Lessons From the Biggest Biotech Event of 2014
Motley Fool
biotech
JPMHC 2014
Sangamo BioSciences
Biogen Idec
Amag Pharmaceuticals
Portola Pharmaceuticals
Flag link:
Why Investors Are Shrugging Off Amag Pharma's Feraheme FDA Rejection
Why Investors Are Shrugging Off Amag Pharma's Feraheme FDA Rejection
TheStreet.com
Amag Pharmaceuticals
FDA
Feraheme
Flag link:
2013 FDA Drug Approval Calendar
2013 FDA Drug Approval Calendar
TheStreet.com
drug approvals
GSK
Dolutegravir
Trametenib
Auxilium
Xiaflex
Delcath
Melblez
Seattle Genetics
Adcetris
Antares
Otrexup
Amag Pharmaceuticals
Feraheme
Cubist Pharmaceuticals
Entereg
Gilead
sofosbuvir
Amarin
Vascepa
Merck
suvorexant
Valeant Pharmaceuticals
efinaconazole
Depomed
Sefelsa
Zogenix
Zohydro
dabrafenib
tivozanib
Aveo Pharmaceuticals
Flag link:
2012 Biotech Stock Predictions: An Interim Report Card
2012 Biotech Stock Predictions: An Interim Report Card
TheStreet.com
Cell Therapeutics
Momenta
Onyx
Amag Pharmaceuticals
Biomarin
M&A
Celgene
Seattle Genetics
Galena Biopharma
ImmunoCellular
Amgen
Celldex
Dendreon
GSK
Vical
Oncothyreon
Biogen Idec
Merck KGaA
Bristol-Myers Squibb
Allos
Spectrum Pharmaceuticals
AstraZeneca
Flag link:
Amag to pitch anemia drug for wider indication
Amag to pitch anemia drug for wider indication
Reuters
anemia
Amag Pharmaceuticals
Feraheme
Flag link:
AMAG To Get $15 Million Milestone Payment From Takeda as Iron Therapy Drug Approved for Europe
AMAG To Get $15 Million Milestone Payment From Takeda as Iron Therapy Drug Approved for Europe
WSJ
Takeda
Amag Pharmaceuticals
anemia
Ferumoxytol
Flag link:
Amag Pharma falls after ending sale talks
Amag Pharma falls after ending sale talks
Yahoo/AP
Amag Pharmaceuticals
M&A
Flag link:
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
Enhanced Online News
Ferumoxytol
Amag Pharmaceuticals
anemia
chronic kidney disease
Flag link:
Biotech 2012 Kickoff Party: Investor Preview
Biotech 2012 Kickoff Party: Investor Preview
TheStreet.com
Celgene
Vivus
Dendreon
Gilead
Incyte
YM BioSciences
ONYX Pharmaceuticals
Seattle Genetics
Vertex
Amarin
Biomarin
Biogen Idec
Regeneron
Merck KGaA
Human Genome Sciences
Clovis Oncology
Roche
Ariad
Immunogen
Medivation
Geron
InterMune
Indenix
Amag Pharmaceuticals
Mesoblast
Arena
MannKind
Keryx
Spectrum Pharmaceuticals
Flag link:
10 Biotech Stock Predictions for 2012
10 Biotech Stock Predictions for 2012
TheStreet.com
Amgen
FDA
Oncothyreon
Merck KGaA
Vical
GSK
Seattle Genetics
M&A
Celgene
Biomarin
Amag Pharmaceuticals
Momenta
ONYX Pharmaceuticals
Cell Therapeutics
Roche
Aeterna Zentaris
Arena Pharmaceuticals
Vertex
Spectrum Pharmaceuticals
Flag link:
2-Star Stocks Poised to Plunge: AMAG Pharmaceuticals?
2-Star Stocks Poised to Plunge: AMAG Pharmaceuticals?
Motley Fool
Amag Pharmaceuticals
Flag link:
AMAG Didn’t Get Sufficient Votes for Acquisition of Allos
AMAG Didn’t Get Sufficient Votes for Acquisition of Allos
Bloomberg
Amag Pharmaceuticals
M&A
Allos
Flag link:

Pages